Similar articles

• Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas.

  Routhier CA, Mochel MC, Lynch K, Dias-Santagata D, Louis DN, Hoang MP. Routhier CA, et al. Hum Pathol. 2013 Nov;44(11):2563-70. doi: 10.1016/j.humpath.2013.06.018. Epub 2013 Sep 24. Hum Pathol. 2013. PMID: 24071017
• In-depth genomic data analyses revealed complex transcriptional and epigenetic dysregulations of BRAFV600E in melanoma.

  Guo X, Xu Y, Zhao Z. Guo X, et al. Mol Cancer. 2015 Mar 14;14:60. doi: 10.1186/s12943-015-0328-y. Mol Cancer. 2015. PMID: 25890285 Free PMC article.
• Common BRAF(V600E)-directed pathway mediates widespread epigenetic silencing in colorectal cancer and melanoma.

  Fang M, Hutchinson L, Deng A, Green MR. Fang M, et al. Proc Natl Acad Sci U S A. 2016 Feb 2;113(5):1250-5. doi: 10.1073/pnas.1525619113. Epub 2016 Jan 19. Proc Natl Acad Sci U S A. 2016. PMID: 26787892 Free PMC article.
• Braf V600E mutation in melanoma: translational current scenario.

  Guadarrama-Orozco JA, Ortega-Gómez A, Ruiz-García EB, Astudillo-de la Vega H, Meneses-García A, Lopez-Camarillo C. Guadarrama-Orozco JA, et al. Clin Transl Oncol. 2016 Sep;18(9):863-71. doi: 10.1007/s12094-015-1469-6. Epub 2016 Jan 29. Clin Transl Oncol. 2016. PMID: 26825657 Review.
• Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies.

  Jang S, Atkins MB. Jang S, et al. Clin Pharmacol Ther. 2014 Jan;95(1):24-31. doi: 10.1038/clpt.2013.197. Epub 2013 Sep 30. Clin Pharmacol Ther. 2014. PMID: 24080641 Review.